Abstract
Rett syndrome (RTT) is one of the most common neurodevelopmental disorders in females. The disease is caused by mutations in the methyl-CpG-binding protein 2 gene (MECP2), and various mutations have been reported. The phenotypic spectrum in both female and male patients is diverse, ranging from very mild to congenital encephalopathy and prenatal lethality. In this study, the question was addressed as to whether implementation of systematic screening of MECP2 in patients with an unexplained mental retardation in DNA diagnostics would be reasonable, and the spectrum of phenotypes resulting from mutations in this gene was further explored. Mutational analysis of MECP2 was performed in mentally retarded female patients who were negative for FMR1 CGG repeat expansion, in male and female patients with clinical features suggestive of either Angelman or Prader-Willi syndrome without methylation defects on chromosome 15q11–q13. In the cohort of females negative for the molecular Fragile-X studies (N=92), one nonsense mutation (p.Q406X) was found. In the cohort of Angelman-negative patients (N=63), two missense mutations (p.R133C in a female patient and a mosaic p.T158M in a male patient) were found, which have been reported many times in patients with classical RTT syndrome. In the Prader-Willi-negative group (N=98), no pathogenic mutations were found.
The results support testing of patients with features suggestive of Angelman syndrome, but without methylation defects on chromosome 15q11–q13 for mutations in MECP2. In the remaining patients with unexplained mental retardation, additional clinical features should determine whether analysis of MECP2 is indicated.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY : Rett syndrome is caused by mutations in X-linked MECP2, encoding the methyl-CpG-binding protein 2. Nat Genet 1999; 23: 185–188.
Trappe R, Laccone F, Cobilanschi J et al: MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet 2001; 68: 1093–1101.
Wan M, Lee SS, Zhang X et al: Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet 1999; 65: 1520–1529.
Hoffbuhr K, Devaney JM, LaFleur B et al: MECP2 mutations in children with and without the phenotype of Rett syndrome. Neurology 2001; 56: 1486–1495.
Sung Jae Lee S, Wan M, Francke U : Spectrum of MECP2 mutations in Rett syndrome. Brain Dev 2001; 23: 138–143.
Hoffbuhr KC, Moses LM, Jerdonek MA, Naidu S, Hoffman EP : Associations between MECP2 mutations, X-chromosome inativation and phenotype. Ment Retard Dev Disabil Res Rev 2002; 8: 99–105.
Villard L, Kpebe A, Cardoso C, Chelly J, Tardieu M, Fontes M : Two affected boys in a Rett syndrome family: clinical and molecular findings. Neurology 2000; 55: 1188–1193.
Orrico A, Lam CW, Galli L et al: MECP2 mutation in male patients with non-specific X-linked mental retardation. FEBS Lett 2000; 481: 285–288.
Couvert P, Bienvenu T, Aquaviva C et al: MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet 2001; 10: 941–946.
Imessaoudene B, Bonnefont JP, Royer G et al: MECP2 mutation in non-fatal, non-progressive encephalopathy in a male. J Med Genet 2001; 38: 171–174.
Watson P, Black G, Ramsden S et al: Angelman syndrome phenotype associated with mutations in MECP2, a gene encoding a methyl CpG binding protein. J Med Genet 2001; 38: 224–228.
Meloni I, Bruttini M, Longo I et al: A mutation in the Rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. Am J Hum Genet 2000; 67: 982–985.
Yntema HG, Kleefstra T, Oudakker AR et al: Low frequency of MECP2 mutations in mentally retarded males. Eur J Hum Genet 2002; 10: 487–490.
Kleefstra T, Yntema HG, Oudakker AR et al: De novo MECP2 frameshift mutation in a boy with moderate mental retardation, obesity and gynaecomastia. Clin Genet 2002; 61: 359–362.
Miller SA, Dykes DD, Polesky HF : A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW : Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 1992; S1: 1229–1239.
Leonard H, Silberstein J, Falk R et al: Occurence of Rett syndrome in boys. J Child Neurol 2001; 16: 33–38.
Topçu M, Cemaliye A, Sayi A et al: Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. Eur J Hum Genet 2002; 10: 77–81.
Clayton-Smith I, Watson P, Ramsden S, Black GCM : Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. Lancet 2000; 356: 830–832.
Acknowledgements
This work was supported by grants from ZonMw.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kleefstra, T., Yntema, H., Nillesen, W. et al. MECP2 analysis in mentally retarded patients: implications for routine DNA diagnostics. Eur J Hum Genet 12, 24–28 (2004). https://doi.org/10.1038/sj.ejhg.5201080
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.ejhg.5201080
Keywords
This article is cited by
-
Progress in Rett Syndrome: from discovery to clinical trials
Wiener Medizinische Wochenschrift (2016)
-
Genetic Approach to Diagnosis of Intellectual Disability
The Indian Journal of Pediatrics (2016)
-
Brief Report: MECP2 Mutations in People Without Rett Syndrome
Journal of Autism and Developmental Disorders (2014)
-
Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized
Nature Reviews Genetics (2006)
-
Mechanisms of Disease: neurogenetics of MeCP2 deficiency
Nature Clinical Practice Neurology (2006)
